MARKET

KNSA

KNSA

KINIKSA PHARMACEUTICALS, LTD.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.29
+0.07
+0.71%
Opening 14:55 09/20 EDT
OPEN
9.20
PREV CLOSE
9.22
HIGH
9.45
LOW
9.01
VOLUME
93.71K
TURNOVER
--
52 WEEK HIGH
32.88
52 WEEK LOW
8.04
MARKET CAP
436.05M
P/E (TTM)
-2.8081
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KNSA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KNSA News

  • The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering
  • Benzinga.7h ago
  • Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research
  • GlobeNewswire.21h ago
  • Kiniksa Highlights Presentation Of Preclinical Data Supporting KPL-716 Development At Annual Meeting of the European Society of Dermatological Research
  • Benzinga.22h ago
  • The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
  • Benzinga.09/05 12:12

More

Industry

Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+1.12%

Hot Stocks

Name
Price
%Change

About KNSA

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.
More

Webull offers Kiniksa Pharmaceuticals Ltd (KNSA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.